In a report issued on December 17, Marc Goodman from Leerink Partners maintained a Hold rating on Satsuma Pharmaceuticals (STSA – Research Report), with a price target of $5.00. The company’s shares closed last Wednesday at $4.65.
According to TipRanks.com, Goodman is a 2-star analyst with an average return of 0.1% and a 42.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Avadel Pharmaceuticals.
Currently, the analyst consensus on Satsuma Pharmaceuticals is a Moderate Buy with an average price target of $10.00.
Based on Satsuma Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $13.34 million. In comparison, last year the company had a GAAP net loss of $12.19 million.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STSA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.
Read More on STSA:
- Leerink Partners Reiterates a Buy Rating on Evolus (EOLS)
- Wells Fargo Believes Ingersoll Rand (IR) Won’t Stop Here
- Leerink Partners Keeps Their Buy Rating on Biohaven Pharmaceutical Holding Co (BHVN)
- Wells Fargo Remains a Hold on Fortive (FTV)
- Axsome Therapeutics (AXSM) Gets a Buy Rating from Leerink Partners